What I’m Grateful For, Thanksgiving 2015

November 24, 2015 10:51 pm

What are you grateful for this Thanksgiving? Annette McElhiney, ovarian cancer survivor and advocate, has much to be thankful for this year and every year. She wrote a post for the Clearity Portal. Read an excerpt below.

I’m grateful to … Read more

Novel Clinical Trial Designs Match Drugs to Patient’s Tumor Profiles

September 1, 2014 8:07 pm

By: Cory Bentley, PhD

Bringing new treatments to ovarian cancer patients is very challenging.  There are not as many patients diagnosed with this cancer as there are with other cancer types, such as breast, lung and colorectal, so there are … Read more

Eligibility Criteria in Clinical Trials: PARP Inhibitors

July 1, 2013 7:59 pm

By: Cory Bentley, PhD

Clearity first reported on drugs inhibiting PARP (Poly-ADP ribose polymerase), an important enzyme for tumor cell proliferation and survival, in its September 2010 patient newsletter.  At that time, PARP inhibitors were just entering clinical trials and

Read more

CA125 Becomes a Target for Destruction of Ovarian Cancer by Phase I Drug

May 1, 2013 7:50 pm

By: Cory Bentley, PhD

Most ovarian cancer patients have become familiar with CA125 blood level monitoring, but trial drug DMUC5754A from Genentech puts a new twist on this familiar blood marker of advanced ovarian cancer. CA125 (cancer antigen 125) also … Read more

Clinical Trials for Ovarian Cancer Patients: Why Now?

February 1, 2013 7:44 pm

By: Cory Bentley, PhD & Teresa Gallagher, PhD

Ovarian cancer is a very diverse disease on the molecular level. Different tumors have different key molecular players and potentially different Achilles’ heels. Researchers are making real progress in pinpointing key players … Read more